Developer docs
API playgroundTry for free, no card

Search company profiles

Space Lintech

Full company profile

uuid0003j11

Namestring
Space Lintech
Legal namestring
SPACELIINTECH
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Space LiinTech is a South Korean space-based biopharma company founded in June 2021 and headquartered in Daejeon that provides microgravity research and manufacturing services to pharmaceutical and biotechnology firms. Its core offering is the BEE (Biomedical Extraterrestrial Enclosure) platform family — standardized and customizable experiment modules compatible with the ISS EXPRESS Rack — anchored by BEE-PC1 (Korea's first protein crystallization module on the ISS, demonstrated August 2025), BEE-1000 (the world's first protein pharmaceutical crystallization module in LEO, launched November 2025 on Nuri Flight 4), and BEE-1012 (scheduled for Nuri Flight 5). These space-based assets are vertically integrated with ground-based microgravity simulation infrastructure including the 600m Jeongseon Drop Tower (co-developed with the Institute for Basic Science), a 900m Taebaek Drop Tower under construction, and the Giheung Gravity Lab for iterative protocol validation. The company also markets Gravito-Electroporation, a proprietary gene-delivery platform for cell therapies combining electroporation with controlled gravity conditions.

Space LiinTech monetizes its platform through four contract-based revenue streams: (1) protein crystallization contract research services addressing Earth-based limitations including convection, secondary nucleation, aggregation, and polymorphism; (2) emerging contract manufacturing for pharmaceuticals and APIs in microgravity using BEE-FRM/FPM modules; (3) ground-based drop tower validation services for transfection research and protocol development; and (4) end-to-end ISS and satellite payload integration, mission operations, and data delivery services. Pricing is determined on a project-by-project basis following detailed scoping of experiment requirements. Target customer segments are large pharmaceutical companies and biotechnology firms (both primary), with CRO/CDMOs as a secondary channel.

The company serves its customers through direct enterprise field sales supplemented by a heavy industry-conference presence (CES 2026, IAC 2025, BIO KOREA 2025) and government engagement, including selection for the Korean ARPA-H Project (December 2024) and Deep Tech TIPS program (June 2023). It has built a strategic partnership network spanning Voyager Technologies (ISS payload integration), Mobilint (AI compute), Innospace and Intergravity (LEO manufacturing platform), Perigee Aerospace (suborbital launches), and Massachusetts General Hospital (BBB drug delivery research), with a global office opened in Boston in December 2025 to support international business development.

Short descriptiontext

Space LiinTech is a South Korean space-based biopharma company that provides microgravity protein crystallization, bioprocess, and gene-delivery research services to pharmaceutical and biotechnology firms, using its proprietary BEE platform modules on the ISS, LEO satellites, and ground-based drop towers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microgravity biopharma, space-based drug discovery, protein crystallization services, in-orbit biomanufacturing, space medicine research
Industry4 codes
PRIMARYIMABACAD
Space Payloads & Instruments (Sensors, Comms, EO/IR)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAIAC
General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens)
SECONDARYIMABACAM
Space Logistics & In-Orbit Servicing (Refueling, Tug, Debris Removal)
NAICS code3 codes
  • Search, Detection, Navigation, Guidance, Aeronautical, and Nautical System and Instrument Manufacturing334511
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Guided Missiles & Space Vehicles & Parts3760
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Space-based Biopharmaceutical Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Research Services - Protein Crystallization
TypeProfessional Services
Description

Space LiinTech provides contract research services for protein crystallization under microgravity conditions on the ISS and LEO satellites. This addresses gravity-related limitations observed on Earth including convection, secondary nucleation, aggregation, and polymorphism. The service supports structure-based drug discovery workflows for pharmaceutical and biotech clients.

spaceliintech.com
2Contract Manufacturing - Pharmaceuticals and APIs
TypeManaged Services
Description

Developing microgravity-enabled production modules and contract-based manufacturing capabilities for pharmaceuticals and active pharmaceutical ingredients (APIs). This supports Korea's growing API ecosystem by exploring scalable production approaches in space with automation, real-time environmental monitoring, and advanced process control.

spaceliintech.com
3Technology Development and Validation Services
TypeProfessional Services
Description

Provides ground-based drop tower experiments and validation services for transfection research and protocol validation. Supports development and validation of space biopharmaceutical technologies including gene delivery workflows for cell and gene therapies.

spaceliintech.com
4ISS and Satellite Payload Services
TypeManaged Services
Description

End-to-end mission support covering payload integration, safety and ISS compatibility processes, mission operations, data delivery, and post-mission analysis for biopharma research in space.

spaceliintech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1BEE Platform
Description

Biomedical Extraterrestrial Enclosure platform for ISS-based biopharma research, including BEE-PC1 for protein crystallization and BEE-1000 for satellite-based research.

spaceliintech.com
+3 more records
Core offering1 text field

Space Lintech provides microgravity-enabled contract research services and biopharma platforms for the pharmaceutical and biotechnology industries. Its core products are the BEE (Biomedical Extraterrestrial Enclosure) platform family—including BEE-PC1, BEE-1000, BEE-1012, and BEE-FRM/FPM—that enable protein crystallization, bioprocess studies, and API manufacturing on the ISS and in LEO satellites. Complementing the space hardware are ground-based drop towers, the Gravito-Electroporation gene delivery platform for cell therapies, and end-to-end payload integration and mission operations services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Korea's first protein crystallization module on the ISS demonstrated successfully in August 2025
+3 more records
Product overview1 text field

Space LiinTech is a space-based biopharma platform company offering an integrated portfolio of microgravity experiment systems and contract research services. The core offering centers on the BEE (Biomedical Extraterrestrial Enclosure) platform family—including BEE-PC1 for ISS-based protein crystallization, BEE-1000 and BEE-1012 for LEO satellite-based research, and BEE-FRM/FPM for in-orbit manufacturing—all compatible with ISS EXPRESS Rack. The company complements space-based operations with ground-based drop tower facilities (Jeongseon 600m, Taebaek 900m, and Giheung Gravity Lab) for iterative testing and protocol validation. The Gravito-Electroporation platform provides proprietary gene delivery technology for cell therapies. Services include contract research for protein crystallization and API manufacturing in microgravity. The company connects ground validation through drop towers with in-orbit research via ISS modules and LEO satellite platforms.

Product and service5 records
1BEE-PC1 (Biomedical Extraterrestrial Enclosure - Protein Crystallization)
CategorySpace Biopharma Hardware Platform
Description

ISS-based autonomous protein crystallization module compatible with the ISS EXPRESS Rack, executing experiments autonomously with minimal astronaut involvement and featuring real-time monitoring through onboard sensors and internal imaging. Intended for pharmaceutical and biotech clients performing structure-based drug discovery.

2BEE-1000 (Biomedical Extraterrestrial Enclosure LEO Satellite Platform)
CategorySpace Biopharma Hardware Platform
Description

LEO satellite-based microgravity biopharma research platform enabling protein crystallization and in-orbit validation. Designed to support scalable biopharma R&D and to provide an alternative to ISS-based experimentation for pharmaceutical and biotech clients.

3Gravito-Electroporation Platform
CategoryCell & Gene Therapy Platform
Description

Proprietary gene delivery technology for cell therapies that combines electroporation with controlled gravity conditions to deliver genetic material across diverse cell types while minimizing cell stress and damage. Used by biotech clients developing cell and gene therapies.

4Space Biopharma Contract Research Services
CategoryContract Research Services
Description

End-to-end contract research services for protein crystallization under microgravity conditions on the ISS and LEO satellites, addressing gravity-related limitations to enable growth of larger and more uniform crystals for high-resolution structural analysis and structure-based drug discovery. Targeted at pharmaceutical and biotech clients.

5Microgravity API Manufacturing Services
CategoryContract Manufacturing Services
Description

Contract-based manufacturing services for pharmaceuticals and active pharmaceutical ingredients (APIs) using microgravity, supporting scalable production approaches in space with automation, real-time environmental monitoring, and advanced process control. Designed for pharmaceutical and biotech manufacturers seeking high-purity biologics and APIs that are challenging to stabilize under Earth gravity.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-06
Description

Strategic business agreement with AI semiconductor company Mobilint to jointly develop an AI space payload utilizing Mobilint's Neural Processing Unit (NPU) technology, optimized for the space environment. The partnership aims to address technical requirements for AI computations under power, heat, and communication constraints while expanding Space LiinTech's space medicine research platform capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

New contract with Voyager Technologies to send research payloads to the International Space Station for microgravity drug discovery. The collaboration focuses on evaluating microgravity's effects on protein crystallization to improve drug formulations and involves testing an AI-driven automation system. Voyager Technologies' stock rose 2.9% following the announcement.

3Innospace and Intergravity
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

MOU signing for commercializing a Low-Earth Orbit Space Medicine Manufacturing Platform. Three-way agreement between Space LiinTech, Innospace (launch vehicle provider), and Intergravity to establish space-based pharmaceutical manufacturing capabilities.

spaceliintech.com
4STEPLab
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

MOU signed with STEPLab for collaboration on space medicine technology development and research initiatives.

spaceliintech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

MOU signed with Voyager Technologies for collaboration on space medicine research and commercial space station initiatives. Voyager Technologies is building starlab, a next-generation commercial space station.

6Handuk Iron Mine
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

MOU signed for microgravity experiment facility operation, utilizing the Handuk Iron Mine vertical shaft for drop tower operations.

spaceliintech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-10
Description

MOU signed to strengthen collaboration with Perigee Aerospace for low-Earth orbit platform research. Space LiinTech signed contract with Perigee Aerospace in November 2023 for suborbital launch vehicle BEE-1000 payload integration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-01
Description

MOU with IBS for collaboration on microgravity research. Space LiinTech established Jeongseon Research Center within IBS Yemi Lab in March 2024. The IBS Jeongseon Drop Tower was developed in collaboration with IBS.

9Jeongseon County
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

MOU signed with Jeongseon County for space medicine research collaboration and drop tower facility support.

spaceliintech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Joint research with Massachusetts General Hospital (MGH), including signed Transfer Agreement for BBB drug delivery effect study under gravity variations. CEO Hargsoon Yoon also served as Visiting Professor at Harvard Medical School.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-based SpacePharma offers end-to-end microgravity research services using miniaturized labs flown on the ISS and suborbital vehicles. Directly competes with Space LiinTech's contract research and protein crystallization offerings, with similar B2B pharma/biotech customer base.

TypeDirect peer
Description

University of Colorado-affiliated BioServe has flown life science and biopharma payloads on the ISS for decades. Competes with Space LiinTech on microgravity biopharma contract research and payload hardware, with similar customer segments in pharma, biotech, and government.

TypeDirect peer
Description

Rhodium Scientific provides contract microgravity research services for biotech, pharma, and academic customers, including ISS experiment design and operations. Closely comparable business model and target customer base to Space LiinTech's contract research offering.

TypeDirect peer
Description

Germany-based Yuri operates microgravity research services and hardware including centrifuge-based and suborbital platforms. Directly comparable as a microgravity R&D services provider targeting pharma and biotech customers, with overlap in protein crystallization and bioprocessing use cases.

TypeBroad incumbent
Description

NYSE-listed Voyager is a commercial space company building Starlab commercial space station and operating ISS services. Functions both as Space LiinTech's named customer/partner and as a broad incumbent in commercial space infrastructure relevant to the same payload ecosystem.

TypeBroad incumbent
Description

Redwire is a publicly listed space hardware and biotech company operating ISS payloads including bioprinting and pharma research platforms. Comparable in space-based life sciences and biomanufacturing, with broader space infrastructure portfolio as a larger incumbent.

TypeEmerging player
Description

LambdaVision uses microgravity on the ISS to manufacture protein-based retinal implants. Niche emerging player focused on a specific microgravity biomanufacturing use case, overlapping with Space LiinTech's BEE-FRM/FPM orbital manufacturing thesis.

TypeEmerging player
Description

Angiex develops antibody-drug conjugates validated on ISS-based microgravity experiments. Emerging biotech using space-based research as part of therapeutic development pipeline, comparable as a customer-side peer leveraging microgravity biopharma platforms.

TypeDirect peer
Description

Space Tango provides ISS-based payload services and microgravity research for biotech, pharma, and technology customers. Directly comparable as a turnkey microgravity R&D services provider with similar hardware-and-service business model.

TypeBroad incumbent
Description

Axiom Space operates commercial ISS missions and is building Axiom Station, a commercial space station. Functions as adjacent infrastructure partner and potential venue for Space LiinTech's biopharma payloads once commercial stations replace ISS.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Space Lintech

Space-based Biopharmaceutical Research Servicesspaceliintech.com

Space LiinTech is a South Korean space-based biopharma company that provides microgravity protein crystallization, bioprocess, and gene-delivery research services to pharmaceutical and biotechnology firms, using its proprietary BEE platform modules on the ISS, LEO satellites, and ground-based drop towers.

What Space Lintech does

Space LiinTech is a South Korean space-based biopharma company founded in June 2021 and headquartered in Daejeon that provides microgravity research and manufacturing services to pharmaceutical and biotechnology firms. Its core offering is the BEE (Biomedical Extraterrestrial Enclosure) platform family — standardized and customizable experiment modules compatible with the ISS EXPRESS Rack — anchored by BEE-PC1 (Korea's first protein crystallization module on the ISS, demonstrated August 2025), BEE-1000 (the world's first protein pharmaceutical crystallization module in LEO, launched November 2025 on Nuri Flight 4), and BEE-1012 (scheduled for Nuri Flight 5). These space-based assets are vertically integrated with ground-based microgravity simulation infrastructure including the 600m Jeongseon Drop Tower (co-developed with the Institute for Basic Science), a 900m Taebaek Drop Tower under construction, and the Giheung Gravity Lab for iterative protocol validation. The company also markets Gravito-Electroporation, a proprietary gene-delivery platform for cell therapies combining electroporation with controlled gravity conditions.

Space LiinTech monetizes its platform through four contract-based revenue streams: (1) protein crystallization contract research services addressing Earth-based limitations including convection, secondary nucleation, aggregation, and polymorphism; (2) emerging contract manufacturing for pharmaceuticals and APIs in microgravity using BEE-FRM/FPM modules; (3) ground-based drop tower validation services for transfection research and protocol development; and (4) end-to-end ISS and satellite payload integration, mission operations, and data delivery services. Pricing is determined on a project-by-project basis following detailed scoping of experiment requirements. Target customer segments are large pharmaceutical companies and biotechnology firms (both primary), with CRO/CDMOs as a secondary channel.

The company serves its customers through direct enterprise field sales supplemented by a heavy industry-conference presence (CES 2026, IAC 2025, BIO KOREA 2025) and government engagement, including selection for the Korean ARPA-H Project (December 2024) and Deep Tech TIPS program (June 2023). It has built a strategic partnership network spanning Voyager Technologies (ISS payload integration), Mobilint (AI compute), Innospace and Intergravity (LEO manufacturing platform), Perigee Aerospace (suborbital launches), and Massachusetts General Hospital (BBB drug delivery research), with a global office opened in Boston in December 2025 to support international business development.

Space Lintech firmographics

Firmographics
Name
Space Lintech
Legal name
SPACELIINTECH
Website
https://spaceliintech.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Space LiinTech is a South Korean space-based biopharma company that provides microgravity protein crystallization, bioprocess, and gene-delivery research services to pharmaceutical and biotechnology firms, using its proprietary BEE platform modules on the ISS, LEO satellites, and ground-based drop towers.
Ownership category
akta.pro rank

Space Lintech industry classification

Industry
Product category
Space-based Biopharmaceutical Research Services
NAICS
Search, Detection, Navigation, Guidance, Aeronautical, and Nautical System and Instrument Manufacturing (334511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Guided Missiles & Space Vehicles & Parts (3760), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYIMABACAD
Space Payloads & Instruments (Sensors, Comms, EO/IR)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAIAC
General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens)
SECONDARYIMABACAM
Space Logistics & In-Orbit Servicing (Refueling, Tug, Debris Removal)

Keywords

  • Microgravity biopharma
  • Space-based drug discovery
  • Protein crystallization services
  • In-orbit biomanufacturing
  • Space medicine research

Where Space Lintech is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Space Lintech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services - Protein Crystallization: Space LiinTech provides contract research services for protein crystallization under microgravity conditions on the ISS and LEO satellites. This addresses gravity-related limitations observed on Earth including convection, secondary nucleation, aggregation, and polymorphism. The service supports structure-based drug discovery workflows for pharmaceutical and biotech clients.
  2. Contract Manufacturing - Pharmaceuticals and APIs: Developing microgravity-enabled production modules and contract-based manufacturing capabilities for pharmaceuticals and active pharmaceutical ingredients (APIs). This supports Korea's growing API ecosystem by exploring scalable production approaches in space with automation, real-time environmental monitoring, and advanced process control.
  3. Technology Development and Validation Services: Provides ground-based drop tower experiments and validation services for transfection research and protocol validation. Supports development and validation of space biopharmaceutical technologies including gene delivery workflows for cell and gene therapies.
  4. ISS and Satellite Payload Services: End-to-end mission support covering payload integration, safety and ISS compatibility processes, mission operations, data delivery, and post-mission analysis for biopharma research in space.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Space Lintech product offering

Product offering

Core offering

Space Lintech provides microgravity-enabled contract research services and biopharma platforms for the pharmaceutical and biotechnology industries. Its core products are the BEE (Biomedical Extraterrestrial Enclosure) platform family—including BEE-PC1, BEE-1000, BEE-1012, and BEE-FRM/FPM—that enable protein crystallization, bioprocess studies, and API manufacturing on the ISS and in LEO satellites. Complementing the space hardware are ground-based drop towers, the Gravito-Electroporation gene delivery platform for cell therapies, and end-to-end payload integration and mission operations services.

Product overview

Space LiinTech is a space-based biopharma platform company offering an integrated portfolio of microgravity experiment systems and contract research services. The core offering centers on the BEE (Biomedical Extraterrestrial Enclosure) platform family—including BEE-PC1 for ISS-based protein crystallization, BEE-1000 and BEE-1012 for LEO satellite-based research, and BEE-FRM/FPM for in-orbit manufacturing—all compatible with ISS EXPRESS Rack. The company complements space-based operations with ground-based drop tower facilities (Jeongseon 600m, Taebaek 900m, and Giheung Gravity Lab) for iterative testing and protocol validation. The Gravito-Electroporation platform provides proprietary gene delivery technology for cell therapies. Services include contract research for protein crystallization and API manufacturing in microgravity. The company connects ground validation through drop towers with in-orbit research via ISS modules and LEO satellite platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • BEE Platform: Biomedical Extraterrestrial Enclosure platform for ISS-based biopharma research, including BEE-PC1 for protein crystallization and BEE-1000 for satellite-based research.
  • BEE-PC1
  • BEE-1000
  • Gravito-Electroporation

Products and services

  • BEE-PC1 (Biomedical Extraterrestrial Enclosure - Protein Crystallization) ISS-based autonomous protein crystallization module compatible with the ISS EXPRESS Rack, executing experiments autonomously with minimal astronaut involvement and featuring real-time monitoring through onboard sensors and internal imaging. Intended for pharmaceutical and biotech clients performing structure-based drug discovery.
  • BEE-1000 (Biomedical Extraterrestrial Enclosure LEO Satellite Platform) LEO satellite-based microgravity biopharma research platform enabling protein crystallization and in-orbit validation. Designed to support scalable biopharma R&D and to provide an alternative to ISS-based experimentation for pharmaceutical and biotech clients.
  • Gravito-Electroporation Platform Proprietary gene delivery technology for cell therapies that combines electroporation with controlled gravity conditions to deliver genetic material across diverse cell types while minimizing cell stress and damage. Used by biotech clients developing cell and gene therapies.
  • Space Biopharma Contract Research Services End-to-end contract research services for protein crystallization under microgravity conditions on the ISS and LEO satellites, addressing gravity-related limitations to enable growth of larger and more uniform crystals for high-resolution structural analysis and structure-based drug discovery. Targeted at pharmaceutical and biotech clients.
  • Microgravity API Manufacturing Services Contract-based manufacturing services for pharmaceuticals and active pharmaceutical ingredients (APIs) using microgravity, supporting scalable production approaches in space with automation, real-time environmental monitoring, and advanced process control. Designed for pharmaceutical and biotech manufacturers seeking high-purity biologics and APIs that are challenging to stabilize under Earth gravity.

Quantifiable outcome

  • Korea's first protein crystallization module on the ISS demonstrated successfully in August 2025
  • +3 more outcomes

Companies that use Space Lintech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Space Lintech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Space Lintech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • MobilintcoreTechnology or Integration · 6 February 2026Strategic business agreement with AI semiconductor company Mobilint to jointly develop an AI space payload utilizing Mobilint's Neural Processing Unit (NPU) technology, optimized for the space environment. The partnership aims to address technical requirements for AI computations under power, heat, and communication constraints while expanding Space LiinTech's space medicine research platform capabilities.
  • Voyager TechnologiescoreStrategic or Co-development Partner · 22 January 2026New contract with Voyager Technologies to send research payloads to the International Space Station for microgravity drug discovery. The collaboration focuses on evaluating microgravity's effects on protein crystallization to improve drug formulations and involves testing an AI-driven automation system. Voyager Technologies' stock rose 2.9% following the announcement.
  • Innospace and IntergravityflagshipStrategic or Co-development Partner · 1 January 2026MOU signing for commercializing a Low-Earth Orbit Space Medicine Manufacturing Platform. Three-way agreement between Space LiinTech, Innospace (launch vehicle provider), and Intergravity to establish space-based pharmaceutical manufacturing capabilities.
  • STEPLabminorStrategic or Co-development Partner · 4 November 2025MOU signed with STEPLab for collaboration on space medicine technology development and research initiatives.
  • Voyager TechnologiescoreStrategic or Co-development Partner · 1 February 2025MOU signed with Voyager Technologies for collaboration on space medicine research and commercial space station initiatives. Voyager Technologies is building starlab, a next-generation commercial space station.
  • Handuk Iron MineminorStrategic or Co-development Partner · 1 August 2023MOU signed for microgravity experiment facility operation, utilizing the Handuk Iron Mine vertical shaft for drop tower operations.
  • Perigee AerospacecoreStrategic or Co-development Partner · 10 December 2022MOU signed to strengthen collaboration with Perigee Aerospace for low-Earth orbit platform research. Space LiinTech signed contract with Perigee Aerospace in November 2023 for suborbital launch vehicle BEE-1000 payload integration.
  • Institute for Basic Science (IBS)coreStrategic or Co-development Partner · 1 February 2022MOU with IBS for collaboration on microgravity research. Space LiinTech established Jeongseon Research Center within IBS Yemi Lab in March 2024. The IBS Jeongseon Drop Tower was developed in collaboration with IBS.
  • Jeongseon CountyminorStrategic or Co-development Partner · 1 October 2021MOU signed with Jeongseon County for space medicine research collaboration and drop tower facility support.
  • Massachusetts General HospitalcoreStrategic or Co-development Partner · 1 April 2021Joint research with Massachusetts General Hospital (MGH), including signed Transfer Agreement for BBB drug delivery effect study under gravity variations. CEO Hargsoon Yoon also served as Visiting Professor at Harvard Medical School.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Space Lintech competitors and assessment

Company assessment

Direct peers

  • SpacePharma: Israel-based SpacePharma offers end-to-end microgravity research services using miniaturized labs flown on the ISS and suborbital vehicles. Directly competes with Space LiinTech's contract research and protein crystallization offerings, with similar B2B pharma/biotech customer base.
  • BioServe Space Technologies: University of Colorado-affiliated BioServe has flown life science and biopharma payloads on the ISS for decades. Competes with Space LiinTech on microgravity biopharma contract research and payload hardware, with similar customer segments in pharma, biotech, and government.
  • Rhodium Scientific: Rhodium Scientific provides contract microgravity research services for biotech, pharma, and academic customers, including ISS experiment design and operations. Closely comparable business model and target customer base to Space LiinTech's contract research offering.
  • Yuri (formerly yuri.gravity): Germany-based Yuri operates microgravity research services and hardware including centrifuge-based and suborbital platforms. Directly comparable as a microgravity R&D services provider targeting pharma and biotech customers, with overlap in protein crystallization and bioprocessing use cases.
  • Space Tango: Space Tango provides ISS-based payload services and microgravity research for biotech, pharma, and technology customers. Directly comparable as a turnkey microgravity R&D services provider with similar hardware-and-service business model.

Broad incumbents

  • Voyager Technologies: NYSE-listed Voyager is a commercial space company building Starlab commercial space station and operating ISS services. Functions both as Space LiinTech's named customer/partner and as a broad incumbent in commercial space infrastructure relevant to the same payload ecosystem.
  • Redwire Corporation: Redwire is a publicly listed space hardware and biotech company operating ISS payloads including bioprinting and pharma research platforms. Comparable in space-based life sciences and biomanufacturing, with broader space infrastructure portfolio as a larger incumbent.
  • Axiom Space: Axiom Space operates commercial ISS missions and is building Axiom Station, a commercial space station. Functions as adjacent infrastructure partner and potential venue for Space LiinTech's biopharma payloads once commercial stations replace ISS.

Emerging players

  • LambdaVision: LambdaVision uses microgravity on the ISS to manufacture protein-based retinal implants. Niche emerging player focused on a specific microgravity biomanufacturing use case, overlapping with Space LiinTech's BEE-FRM/FPM orbital manufacturing thesis.
  • Angiex: Angiex develops antibody-drug conjugates validated on ISS-based microgravity experiments. Emerging biotech using space-based research as part of therapeutic development pipeline, comparable as a customer-side peer leveraging microgravity biopharma platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Space Lintech social profiles

Digital presence

Space Lintech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Space Lintech leadership team

Management profile

Number of profiles

Profiles6 records

Space Lintech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Space Lintech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Space Lintech

What does Space Lintech do?

Space Lintech provides microgravity-enabled contract research services and biopharma platforms for the pharmaceutical and biotechnology industries. Its core products are the BEE (Biomedical Extraterrestrial Enclosure) platform family—including BEE-PC1, BEE-1000, BEE-1012, and BEE-FRM/FPM—that enable protein crystallization, bioprocess studies, and API manufacturing on the ISS and in LEO satellites. Complementing the space hardware are ground-based drop towers, the Gravito-Electroporation gene delivery platform for cell therapies, and end-to-end payload integration and mission operations services.

Is Space Lintech a public or private company?

Space Lintech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Space Lintech founded?

Space Lintech was founded in 2021. It employs 11 to 50 people.

Where is Space Lintech based?

Space Lintech is headquartered in Daejeon, South Korea, in the Asia region.

How does Space Lintech make money?

Four revenue lines are on record. Contract Research Services - Protein Crystallization is the primary driver. The others are contract Manufacturing - Pharmaceuticals and APIs, technology Development and Validation Services and ISS and Satellite Payload Services.

Who are Space Lintech's main competitors?

Direct peers on record are SpacePharma, BioServe Space Technologies, Rhodium Scientific, Yuri (formerly yuri.gravity) and Space Tango. Broad incumbents are Voyager Technologies, Redwire Corporation and Axiom Space. Emerging players are LambdaVision and Angiex.

Does Space Lintech have an API?

No public API is recorded for Space Lintech.

What industry is Space Lintech in?

Space Lintech's product category is Space-based Biopharmaceutical Research Services. Its primary akta.pro industry code is IMABACAD, Space Payloads & Instruments (Sensors, Comms, EO/IR), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334511 and its SIC code is 3760.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldThe next drug lab is in orbitKorean biotech firms Space LiinTech and Boryung are leading the country's entry into space-based drug discovery, leveraging microgravity to grow higher-quality protein crystals and antibodies for next-generation therapies. Space LiinTech has sent experimental pharmaceutical modules to the International Space Station and Low-Earth Orbit, with plans for multiple launches this year and next, while Boryung has invested $60 million in Axiom Space and $10 million in Intuitive Machines to secure access to commercial space infrastructure. Industry experts are calling for a nationwide K-SpaceBio consortium and regulatory frameworks to position Korea competitively against the US, Japan, EU and China in this emerging field.InvestorsHiked Outlook, ISS Experiment Deal Send 2 Defense Stocks SurgingBooz Allen Hamilton reported Q3 2026 adjusted earnings of $1.77 per share, up 14.2%, though revenue fell 10.2% to $2.6 billion due to last year's government shutdown, and the company raised its 2026 EPS guidance to $5.95-$6.15 per share. Voyager Technologies announced a new contract with Space LinnTech to develop a payload for the International Space Station enabling microgravity drug experiments, with shares jumping 7.3%. Both defense stocks surged on Friday—Booz Allen Hamilton rose 6.8% and Voyager Technologies gained 7.3%—as investors reacted positively to the earnings beat and new contract announcement.ChosunbizSpace LiinTech secures Series B funding to advance Korea's space medicine sectorSpace LiinTech secured Series B funding on the 10th, with new investors including K Partners, Sunbo Angel Partners, Stick Ventures, KODIT, and D.CAMP. The company will launch Korea's first space medicine research module to the ISS in August. It is also developing automated experimental devices with KIST and Harvard Medical School.PR NewswireVoyager Technologies Adds Space-Based Biopharma Company Space LiinTech to GWC Science ParkVoyager Technologies added South Korea-based Space LiinTech to its GWC Science Park at The Ohio State University. The space-based biopharma company will access workshops, technical services, and OSU hardware, aiming to broaden international cooperation in space-based biopharma. Voyager plans to use the park for cooperative research and education on microgravity and orbital techniques.